What is LB Pharmaceuticals Inc Common Stock (LBRX) stock price today?

LB Pharmaceuticals Inc Common Stock (LBRX) currently trades at $31.71 per share. The stock has a market capitalization of $912.17M and a P/E ratio of —x.

Is LBRX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, LB Pharmaceuticals Inc Common Stock has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -6.60.

Is LB Pharmaceuticals Inc Common Stock financially healthy?

LB Pharmaceuticals Inc Common Stock's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -6.60 places it in the distress.

LBRX

LB Pharmaceuticals Inc Common Stock

NASDAQ: LBRX · HEALTHCARE · BIOTECHNOLOGY

$31.71

+3.66% today

Updated 2026-04-30

Market cap

$912.17M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.13

Dividend yield

—

52W range

$13 – $33

Volume

0.3M

Market cap

$912.17M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.13

Dividend yield

—

52W range

$13 – $33

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-6.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$44.00

+38.76%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -6.60 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-18.14M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-14.35M	$-6.28M	$-63.10M	$-25.20M	$-11.47M
EPS	—	—	—	—	$-3.13
Free cash flow	$-2.73M	$-12.12M	$-53.82M	$-35.26M	$-18.14M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LBRX	$912.17M	28	4.3	3.0	5.0	6.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

LB Pharmaceuticals Inc Common Stock trades at $31.71. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.60, it sits in the distress.

Frequently asked questions

What is LB Pharmaceuticals Inc Common Stock's stock price?

LB Pharmaceuticals Inc Common Stock (LBRX) trades at $31.71.

Is LB Pharmaceuticals Inc Common Stock overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of LB Pharmaceuticals Inc Common Stock (LBRX)?

The analyst target price is $44.00, representing +38.8% upside from the current price of $31.71.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-6.60 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

lbpharma.us

Quick metrics

P/S ratio—

ROE-15.70%

Beta—

50D MA$25.64

200D MA$20.73

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.3M

Performance

1 week+1.97%

1 month+27.25%

3 months+48.23%

YTD+40.97%

1 year—

3 years—

5 years—

Compare

LBRX vs LLY →LBRX vs JNJ →LBRX vs ABBV →Stock screener →